{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:40:29Z","timestamp":1772826029716,"version":"3.50.1"},"reference-count":37,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/13696998.2024.2322394","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T08:35:00Z","timestamp":1708590900000},"page":"473-481","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7378-1675","authenticated-orcid":false,"given":"Siguroli","family":"Teitsson","sequence":"first","affiliation":[{"name":"Bristol Myers Squibb","place":["Uxbridge, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-233X","authenticated-orcid":false,"given":"Thor-Henrik","family":"Brodtkorb","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["Ljungskile, Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Kurt","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Princeton, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3543-1420","authenticated-orcid":false,"given":"Miraj Y.","family":"Patel","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Princeton, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayla","family":"Poretta","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Princeton, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Knight","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["Manchester, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzam","family":"Kamgar","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["Ljungskile, Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7268-2560","authenticated-orcid":false,"given":"Stephen","family":"Palmer","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York","place":["York, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"American Cancer Society. What is bladder cancer? 2022. https:\/\/www.cancer.org\/cancer\/types\/bladder-cancer\/about\/what-is-bladder-cancer.html."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.05.042"},{"key":"e_1_3_5_4_1","unstructured":"Johns Hopkins Greenberg Bladder Cancer Institute. Upper tract urothelial cancer. 2017. https:\/\/www.hopkinsmedicine.org\/greenberg-bladder-cancer-institute\/utuc\/."},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2018.09.11"},{"key":"e_1_3_5_6_1","volume-title":"Cancer staging form supplement","author":"American Joint Committee on Cancer","year":"2018","unstructured":"American Joint Committee on Cancer. Cancer staging form supplement. 8th ed. New York: Springer; 2018.","edition":"8"},{"key":"e_1_3_5_7_1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Bladder Cancer; V.5.2020."},{"key":"e_1_3_5_8_1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Bladder Cancer; V.1. 2020. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp."},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"e_1_3_5_10_1","unstructured":"US Food and Drug Administration. FDA approves nivolumab for adjuvant treatment of urothelial carcinoma; 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma."},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442"},{"key":"e_1_3_5_12_1","volume-title":"Presented at: Society for Urologic Oncology 22nd Annual Meeting, December 1-3, Orlando, FL, USA","author":"Galsky MD","year":"2021","unstructured":"Galsky MD, Witjes JA, Gschwend JE, et\u00a0al. Disease-free survival with longer follow-up from the phase 3 CheckMate 274 trial of adjuvant nivolumab in patients who underwent surgery for high-risk muscle-invasive urothelial carcinoma. Presented at: Society for Urologic Oncology 22nd Annual Meeting, December 1-3, Orlando, FL, USA, 2021."},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2329019"},{"key":"e_1_3_5_14_1","unstructured":"Woods B Sideris E Palmer S et\u00a0al. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. Report by the Decision Support Unit. 2017. https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/TSD19-Partitioned-Survival-Analysis-final-report.pdf."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-019-00513-3"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.986"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1824"},{"key":"e_1_3_5_18_1","unstructured":"National Institute for Health and Care Excellence. NICE-TA424. Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer [ID767]. 2016. https:\/\/www.nice.org.uk\/guidance\/ta424\/documents\/committee-papers-2."},{"key":"e_1_3_5_19_1","unstructured":"National Institute for Health and Care Excellence. NICE-TA569. Pertuzumab for adjuvant treatment of HER2-positive early breast cancer [ID1192]. 2018. https:\/\/www.nice.org.uk\/guidance\/ta569\/documents\/committee-papers."},{"key":"e_1_3_5_20_1","unstructured":"National Institute for Health and Care Excellence. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma. Technology appraisal guidance [TA544]. 2018. https:\/\/www.nice.org.uk\/guidance\/ta544."},{"key":"e_1_3_5_21_1","unstructured":"National Institute for Health and Care Excellence. NICE-TA580. Enzalutamide for treating non metastatic hormone-relapsed prostate cancer [ID1359]. 2019. https:\/\/www.nice.org.uk\/guidance\/ta580\/evidence\/appraisal-consultation-committee-papers-pdf-6781040029."},{"key":"e_1_3_5_22_1","unstructured":"National Institute for Health and Care Excellence. NICE-TA612. Neratinib for extended adjuvant treatment of hormone receptor-positive HER2-positive early stage breast cancer after adjuvant trastuzumab [ID981]. 2019. https:\/\/www.nice.org.uk\/guidance\/ta612\/evidence\/appraisal-consultation-committee-papers-pdf-6967189694."},{"key":"e_1_3_5_23_1","unstructured":"National Institute for Health and Care Excellence. NICE-TA632. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [ID1516]. 2020. https:\/\/www.nice.org.uk\/guidance\/ta632\/evidence\/committee-papers-pdf-8771187997."},{"key":"e_1_3_5_24_1","unstructured":"National Institute for Health and Care Excellence. NICE-TA761. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835]. 2021. https:\/\/www.nice.org.uk\/guidance\/ta761\/documents\/committee-papers-3."},{"key":"e_1_3_5_25_1","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma. Technology appraisal guidance [TA766]. 2022. https:\/\/www.nice.org.uk\/guidance\/ta766."},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2014.03.011"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10455.x"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.08.032"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.10.007"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-020-00245-4"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6979"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12472398"},{"key":"e_1_3_5_33_1","unstructured":"Rutherford MJ Lambert PC Sweeting MJ et\u00a0al. NICE DSU technical support document 21: flexible methods for survival analysis. 2020. http:\/\/www.nicedsu.org.uk."},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.08.010"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.08.004"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.476"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16639900"},{"key":"e_1_3_5_38_1","unstructured":"National Institute for Health and Care Excellence. Pertuzumab for adjuvant treatment of early HER2-positive breast cancer. Technology appraisal guidance [TA569]. 2019. https:\/\/www.nice.org.uk\/guidance\/ta569."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2024.2322394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:45:33Z","timestamp":1772779533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2024.2322394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/13696998.2024.2322394"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2024.2322394","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}